262 related articles for article (PubMed ID: 16428745)
1. Comparative safety and immunogenicity of two attenuated enterotoxigenic Escherichia coli vaccine strains in healthy adults.
McKenzie R; Bourgeois AL; Engstrom F; Hall E; Chang HS; Gomes JG; Kyle JL; Cassels F; Turner AK; Randall R; Darsley M; Lee C; Bedford P; Shimko J; Sack DA
Infect Immun; 2006 Feb; 74(2):994-1000. PubMed ID: 16428745
[TBL] [Abstract][Full Text] [Related]
2. A double-blind, placebo-controlled trial to evaluate the efficacy of PTL-003, an attenuated enterotoxigenic E. coli (ETEC) vaccine strain, in protecting against challenge with virulent ETEC.
McKenzie R; Darsley M; Thomas N; Randall R; Carpenter C; Forbes E; Finucane M; Sack RB; Hall E; Bourgeois AL
Vaccine; 2008 Aug; 26(36):4731-9. PubMed ID: 18602960
[TBL] [Abstract][Full Text] [Related]
3. Construction and phase I clinical evaluation of the safety and immunogenicity of a candidate enterotoxigenic Escherichia coli vaccine strain expressing colonization factor antigen CFA/I.
Turner AK; Beavis JC; Stephens JC; Greenwood J; Gewert C; Thomas N; Deary A; Casula G; Daley A; Kelly P; Randall R; Darsley MJ
Infect Immun; 2006 Feb; 74(2):1062-71. PubMed ID: 16428753
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the antibody in lymphocyte supernatant (ALS) and ELISPOT assays for detection of mucosal immune responses to antigens of enterotoxigenic Escherichia coli in challenged and vaccinated volunteers.
Carpenter CM; Hall ER; Randall R; McKenzie R; Cassels F; Diaz N; Thomas N; Bedford P; Darsley M; Gewert C; Howard C; Sack RB; Sack DA; Chang HS; Gomes G; Bourgeois AL
Vaccine; 2006 May; 24(18):3709-18. PubMed ID: 16153753
[TBL] [Abstract][Full Text] [Related]
5. Safety and immunogenicity of an improved oral inactivated multivalent enterotoxigenic Escherichia coli (ETEC) vaccine administered alone and together with dmLT adjuvant in a double-blind, randomized, placebo-controlled Phase I study.
Lundgren A; Bourgeois L; Carlin N; Clements J; Gustafsson B; Hartford M; Holmgren J; Petzold M; Walker R; Svennerholm AM
Vaccine; 2014 Dec; 32(52):7077-84. PubMed ID: 25444830
[TBL] [Abstract][Full Text] [Related]
6. Dose-dependent circulating immunoglobulin A antibody-secreting cell and serum antibody responses in Swedish volunteers to an oral inactivated enterotoxigenic Escherichia coli vaccine.
Jertborn M; Ahrén C; Svennerholm AM
Clin Diagn Lab Immunol; 2001 Mar; 8(2):424-8. PubMed ID: 11238232
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the safety and immunogenicity of the oral inactivated multivalent enterotoxigenic Escherichia coli vaccine ETVAX in Bangladeshi adults in a double-blind, randomized, placebo-controlled Phase I trial using electrochemiluminescence and ELISA assays for immunogenicity analyses.
Akhtar M; Chowdhury MI; Bhuiyan TR; Kaim J; Ahmed T; Rafique TA; Khan A; Rahman SIA; Khanam F; Begum YA; Sharif MZ; Islam LN; Carlin N; Maier N; Fix A; Wierzba TF; Walker RI; Bourgeois AL; Svennerholm AM; Qadri F; Lundgren A
Vaccine; 2019 Sep; 37(37):5645-5656. PubMed ID: 30473185
[TBL] [Abstract][Full Text] [Related]
8. Clinical trial to evaluate safety and immunogenicity of an oral inactivated enterotoxigenic Escherichia coli prototype vaccine containing CFA/I overexpressing bacteria and recombinantly produced LTB/CTB hybrid protein.
Lundgren A; Leach S; Tobias J; Carlin N; Gustafsson B; Jertborn M; Bourgeois L; Walker R; Holmgren J; Svennerholm AM
Vaccine; 2013 Feb; 31(8):1163-70. PubMed ID: 23306362
[TBL] [Abstract][Full Text] [Related]
9. Reduced doses of oral killed enterotoxigenic Escherichia coli plus cholera toxin B subunit vaccine is safe and immunogenic in Bangladeshi infants 6-17 months of age: dosing studies in different age groups.
Qadri F; Ahmed T; Ahmed F; Begum YA; Sack DA; Svennerholm AM;
Vaccine; 2006 Mar; 24(10):1726-33. PubMed ID: 16257098
[TBL] [Abstract][Full Text] [Related]
10. A combination vaccine consisting of three live attenuated enterotoxigenic Escherichia coli strains expressing a range of colonization factors and heat-labile toxin subunit B is well tolerated and immunogenic in a placebo-controlled double-blind phase I trial in healthy adults.
Harro C; Sack D; Bourgeois AL; Walker R; DeNearing B; Feller A; Chakraborty S; Buchwaldt C; Darsley MJ
Clin Vaccine Immunol; 2011 Dec; 18(12):2118-27. PubMed ID: 21994354
[TBL] [Abstract][Full Text] [Related]
11. Genetically modified enterotoxigenic Escherichia coli vaccines induce mucosal immune responses without inflammation.
Daley A; Randall R; Darsley M; Choudhry N; Thomas N; Sanderson IR; Croft NM; Kelly P
Gut; 2007 Nov; 56(11):1550-6. PubMed ID: 17566016
[TBL] [Abstract][Full Text] [Related]
12. Attenuated Escherichia coli strains expressing the colonization factor antigen I (CFA/I) and a detoxified heat-labile enterotoxin (LThK63) enhance clearance of ETEC from the lungs of mice and protect mice from intestinal ETEC colonization and LT-induced fluid accumulation.
Byrd W; Boedeker EC
Vet Immunol Immunopathol; 2013 Mar; 152(1-2):57-67. PubMed ID: 23122616
[TBL] [Abstract][Full Text] [Related]
13. Safety, tolerability, and immunogenicity of an oral inactivated ETEC vaccine (ETVAX®) with dmLT adjuvant in healthy adults and children in Zambia: An age descending randomised, placebo-controlled trial.
Sukwa N; Mubanga C; Hatyoka LM; Chilyabanyama ON; Chibuye M; Mundia S; Munyinda M; Kamuti E; Siyambango M; Badiozzaman S; Bosomprah S; Carlin N; Kaim J; Sjöstrand B; Simuyandi M; Chilengi R; Svennerholm AM
Vaccine; 2023 Nov; 41(46):6884-6894. PubMed ID: 37838479
[TBL] [Abstract][Full Text] [Related]
14. Prime-boost vaccine regimen confers protective immunity to human-derived enterotoxigenic Escherichia coli.
Lasaro MO; Luiz WB; Sbrogio-Almeida ME; Ferreira LC
Vaccine; 2005 Mar; 23(19):2430-8. PubMed ID: 15752829
[TBL] [Abstract][Full Text] [Related]
15. Immunogenicity and protective efficacy of a single-dose live non-pathogenic Escherichia coli oral vaccine against F4-positive enterotoxigenic Escherichia coli challenge in pigs.
Fairbrother JM; Nadeau É; Bélanger L; Tremblay CL; Tremblay D; Brunelle M; Wolf R; Hellmann K; Hidalgo Á
Vaccine; 2017 Jan; 35(2):353-360. PubMed ID: 27916413
[TBL] [Abstract][Full Text] [Related]
16. Administration of purified colonization factor antigens (CFA/I, CFA/II) of enterotoxigenic Escherichia coli to volunteers. Response to challenge with virulent enterotoxigenic Escherichia coli.
Evans DG; Graham DY; Evans DJ
Gastroenterology; 1984 Oct; 87(4):934-40. PubMed ID: 6381216
[TBL] [Abstract][Full Text] [Related]
17. Transcutaneous immunization with the heat-labile toxin (LT) of enterotoxigenic Escherichia coli (ETEC): protective efficacy in a double-blind, placebo-controlled challenge study.
McKenzie R; Bourgeois AL; Frech SA; Flyer DC; Bloom A; Kazempour K; Glenn GM
Vaccine; 2007 May; 25(18):3684-91. PubMed ID: 17313998
[TBL] [Abstract][Full Text] [Related]
18. Development and preclinical evaluation of safety and immunogenicity of an oral ETEC vaccine containing inactivated E. coli bacteria overexpressing colonization factors CFA/I, CS3, CS5 and CS6 combined with a hybrid LT/CT B subunit antigen, administered alone and together with dmLT adjuvant.
Holmgren J; Bourgeois L; Carlin N; Clements J; Gustafsson B; Lundgren A; Nygren E; Tobias J; Walker R; Svennerholm AM
Vaccine; 2013 May; 31(20):2457-64. PubMed ID: 23541621
[TBL] [Abstract][Full Text] [Related]
19. Safety and immunogenicity of a single oral dose of recombinant double mutant heat-labile toxin derived from enterotoxigenic Escherichia coli.
El-Kamary SS; Cohen MB; Bourgeois AL; Van De Verg L; Bauers N; Reymann M; Pasetti MF; Chen WH
Clin Vaccine Immunol; 2013 Nov; 20(11):1764-70. PubMed ID: 24049109
[TBL] [Abstract][Full Text] [Related]
20. Immunogenicity of multivalent Shigella-ETEC candidate vaccine strains in a guinea pig model.
Barry EM; Wang J; Wu T; Davis T; Levine MM
Vaccine; 2006 May; 24(18):3727-34. PubMed ID: 16169130
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
